Immunoway/Afuresertib (GSK2110183)/10mg 50mg 100mg/MC0929
市场价：
¥6000.00
美元价：
3000.00
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
Afuresertib (GSK2110183)
- Catalog No.：MC0929
- Data Sheet
- MSDS
- Support
- Description
- References ( 0 )
- Protocol
- CasNo：
- 1047644-62-1
- MolecularFormula：
- C18H17Cl2FN4OS
- Purity：
- >98%
- Target：
- Akt
- IC50：
- Ki: 0.08 nM (AKT1), 2 nM (AKT2), 2.6 nM (AKT3)[1] IC50: 0.2 nM (AKT1E17K), 1.3 nM (PKA), 0.9 nM (PKG1α), 4 nM (PKG1β)[1]
- In Vitro：
- Afuresertib (GSK2110183) shows concentration-dependent effect on multiple AKT substrate phosphorylation levels, including GSK3β, PRAS40, FOXO and Caspase 9 in both BT474 and LNCaP cell lines. GSK2110183 consistently has potent anti-proliferative effects on a variety of hematological malignancies. Overall 65% of the hematological cell lines are sensitive to GSK2110183 (EC50<1 µm).="" among="" solid="" tumor="" cell="" lines,="" 21%="" have=""><1 µm="" in="" response="" to="" gsk2110183[1].="">
- In Vivo：
- Mice bearing BT474 breast tumor xenografts are dosed orally with either vehicle or GSK2110183 at 10, 30 or 100 mg/kg daily for 21 days which results in 8, 37 and 61% tumor growth inhibition (TGI), respectively. Mice tolerates GSK2110183 well, with 1-3% body weight loss reported after 5 days of dosing which recovers over the course of the study. Other tumor xenograft models which possess an activation of the AKT pathway are explored to further demonstrate compound efficacy. Mice bearing SKOV3 ovarian tumor xenografts with 10, 20 and 30 mg/kg GSK2141795 QD displays a 73, 85 or 93% TGI, respectively, compared to vehicle control. Similarly, mice treated with GSK2110183 at 10, 30 and 100 mg/kg results in 23, 37 and 97% TGI, respectively, of SKOV3 xenografts[1].
- Fields：
- Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2. Ki: 0.08 nM (AKT1), 2 nM (AKT2), 2.6 nM (AKT3)[1] IC50: 0.2 nM (AKT1E17K), 1.3 nM (PKA), 0.9 nM (PKG1α), 4 nM (PKG1β)[1]
- Specificity：
- Target: Akt . Fields: Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2. Ki: 0.08 nM (AKT1),
- Source：
- Rabbit
- Dilution：
- Ki: 0.08 nM (AKT1), 2 nM (AKT2), 2.6 nM (AKT3)[1] IC50: 0.2 nM (AKT1E17K), 1.3 nM (PKA), 0.9 nM (PKG1α), 4 nM (PKG1β)[1]
- Concentration：
- >98%
- Storage Stability：
- 2 years -20°C Powder, 2 weeks4°C in DMSO,6 months-80°C in DMSO
- MolecularWeight(Da)：
- 427.32
- References：
- [1]. Dumble M, et al. Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor. PLoS One. 2014 Jun 30;9(6):e100880.
- June 19-2018
- WESTERN IMMUNOBLOTTING PROTOCOL
- June 19-2018
- IMMUNOHISTOCHEMISTRY-PARAFFIN PROTOCOL
- June 19-2018
- IMMUNOFLUORESCENCE PROTOCOL
- September 08-2020
- FLOW-CYTOMEYRT-PROTOCOL
- July 13-2018
- CELL-BASED-ELISA-PROTOCOL-FOR-ACETYL-PROTEIN
- July 13-2018
- CELL-BASED-ELISA-PROTOCOL-FOR-PHOSPHO-PROTEIN
- July 13-2018
- CELL-BASED-COLORIMETRIC-ELISA-PROTOCOL-FOR-TOTAL-PROTEIN
- July 13-2018
- Antibody-FAQs
- Products Images
品牌介绍
ImmunowayImmunoWay Biotechnology，我们的使命是帮助世界各地的生命科学研究人员通过更好的产品和服务简化和加速他们的研究。我们专注于开发用于免疫学和细胞学检测的创新和可靠的产品。我们一直是开发高质量ELISA试剂盒，代谢检测试剂盒，抗体和抗体/蛋白质微阵列的先驱，参与癌症，细胞凋亡，细胞生长和信号转导。ImmunoWay Biotechnology，我们的使命是通过更好的产品和服务帮助世界各地的生命科学研究者简化和加速他们的研究。我们专注于开发创新和可靠的产品，用于免疫学和细胞学检测。我们一直是开发涉及癌症，细胞凋亡，细胞生长和信号转导的高质量ELISA试剂盒，代谢测定试剂盒，抗体和抗体/蛋白质微阵列的先驱。
品牌分类
\Elisa试剂盒\
联络我们
